التفاصيل البيبلوغرافية
| العنوان: |
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. |
| المؤلفون: |
Burdet, C., Pajot, O., Couffignal, C., Armand-Lefèvre, L., Foucrier, A., Laouénan, C., Wolff, M., Massias, L., Mentré, F. |
| المصدر: |
European Journal of Clinical Pharmacology; Jan2015, Vol. 71 Issue 1, p75-83, 9p, 2 Charts, 4 Graphs |
| مصطلحات موضوعية: |
PNEUMONIA diagnosis, ALGORITHMS, CONFIDENCE intervals, CRITICALLY ill, LONGITUDINAL method, MEDICAL cooperation, PATIENTS, PNEUMONIA, RESEARCH, RESEARCH funding, MECHANICAL ventilators, DESCRIPTIVE statistics, AMIKACIN, IMIPENEM |
| مصطلحات جغرافية: |
FRANCE |
| مستخلص: |
Aims: Modifications of antimicrobials' pharmacokinetic parameters have been reported in critically ill patients, resulting in a risk of treatment failure. We characterized amikacin pharmacokinetic variability in critically ill patients with ventilator-associated pneumonia (VAP) and evaluated several dosing regimens. Methods: We conducted a prospective multicenter study in critically ill patients with presumptive diagnosis of Gram-negative bacilli (GNB) VAP. Patients empirically received imipenem and a single-dose of amikacin, which was administered as a 30-min infusion (20 mg/kg). Concentrations were measured 0.5, 1, 8, 16, and 24 h after beginning of infusion. Pharmacokinetic parameters were estimated using a population approach. Main pharmacodynamic target was a ratio ≥10 between the concentration achieved 1 h after beginning of infusion ( C) and the minimal inhibitory concentration of the liable bacteria (MIC). We simulated individual C for several dosing regimens by Monte Carlo method and computed C/MIC ratios for MICs from 0.5 to 64 mg/L. Results: Sixty patients (47 males), median (range) age, and body weight, 61.5 years (28-84) and 78 kg (45-126), respectively, were included. Amikacin median C was 45 mg/L (22-87). Mean value (between-patients variability) for CL, V1, Q, and V2 were 4.3 L/h (31 %), 15.9 L (22 %), 12.1 L/h (27 %), and 21.4 L (47 %), respectively. CL increased with CrCL ( p < 0.001) and V1 with body weight ( p < 0.001) and PaO/FIO ratio ( p < 0.001). With a 25 mg/kg regimen, the pharmacodynamic target was achieved in 20 and 96 % for a MICs of 8 and 4 mg/L, respectively. Conclusion: Amikacin clearance was decreased and its volume of distribution was increased as previously reported. A ≥25 mg/kg single-dose is needed for empirical treatment of GNB-VAP. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Clinical Pharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
